低通量DNA测序检测染色体臂水平异常表征异型增生肝结节及血液游离DNA验证
该研究利用低通量全基因组测序分析184例肝硬变、异型增生结节和肝细胞癌组织,发现1q+或8q+臂水平重复与高风险病理(肝细胞癌或高级别异型增生结节)显著相关(OR分别为35.5和16);并在独立队列中验证血液游离DNA可检出至少两种染色体臂水平改变(1q+、4q-、8p-、8q+),提示其作为肝硬化患者早期筛查工具的潜力。
要点
- 1q+或8q+臂水平重复与肝细胞癌或高级别异型增生结节高风险病理显著相关。
- 低通量测序可检测组织及血液游离DNA中的染色体臂水平体细胞拷贝数改变。
- 血液游离DNA中至少两种改变(1q+、4q-、8p-、8q+)在肝细胞癌患者可检出。
核心结论
- 1q+或8q+臂水平体细胞拷贝数改变与高风险肝脏病理(肝细胞癌或高级别异型增生结节)相关。
- 血液游离DNA低通量测序可检测这些改变,可能成为肝硬化患者未来早期癌症筛查工具。
研究设计与样本
- 利用389例肝细胞癌患者非癌DNA序列建立阈值以最小化假阳性体细胞拷贝数改变。
- 对184例代表肝细胞癌变多步骤过程的组织样本进行低通量全基因组测序。
- 独立验证队列来自英国诺丁汉,包括22例肝细胞癌和9例肝硬化对照患者,检测血液游离DNA。
主要发现
- 1q+或8q+臂水平重复样本更可能为肝细胞癌或高级别异型增生结节而非低级别异型增生结节或肝硬化组织,OR分别为35.5(95%CI 11.5-110)和16(95%CI 6.4-40.2),p<0.0001。
- 独立验证队列中,22例肝细胞癌患者血液游离DNA可检出四种改变(1q+、4q-、8p-、8q+)中至少两种,而9例肝硬化对照患者均未检出。
关键数值与推荐
- 1q+或8q+臂水平重复鉴别高风险病理的OR为35.5(95%CI 11.5-110)和16(95%CI 6.4-40.2),p<0.0001。
- 血液游离DNA中至少检出四种改变(1q+、4q-、8p-、8q+)中的两种可区分肝细胞癌与肝硬化对照。
临床怎么用
- 对肝硬化患者可考虑低通量测序检测血液游离DNA中1q+、4q-、8p-、8q+等臂水平改变以辅助早期筛查。
- 组织学评估困难时,1q+或8q+臂水平重复可辅助识别高级别异型增生结节等高危病变。
局限性
- 血液游离DNA验证队列样本量较小(肝细胞癌22例,肝硬化对照9例)。
- 研究为回顾性设计,未来筛查工具价值需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-grade dysplasia carries significant risk of transformation to hepatocellular carcinoma (HCC). Despite this, at the current standard of care, all non-malignant hepatic nodules including high-grade dysplastic nodules are managed similarly. This is partly related to difficulties in distinguishing high-risk pathology in the liver. We aimed to identify chromosome arm-level somatic copy number alterations (SCNAs) that characterise the transition of liver nodules along the cirrhosis-dysplasia-carcinoma axis. We validated our findings on an independent cohort using blood-derived cell-free DNA. A repository of non-cancer DNA sequences obtained from patients with HCC (n = 389) was analysed to generate cut-off thresholds aiming to minimise false-positive SCNAs. Tissue samples representing stages from the multistep process of hepatocarcinogenesis (n = 184) were subjected to low-pass whole genome sequencing. Chromosome arm-level SCNAs were identified in liver cirrhosis, dysplastic nodules, and HCC to assess their discriminative capacity. Samples positive for 1q+ or 8q+ arm-level duplications were likely to be either HCC or high-grade dysplastic nodules as opposed to low-grade dysplastic nodules or cirrhotic tissue with an odds ratio (OR) of 35.5 (95% CI 11.5-110) and 16 (95% CI 6.4-40.2), respectively (p < 0.0001). In an independent cohort of patients recruited from Nottingham, UK, at least two out of four alterations (1q+, 4q-, 8p-, and 8q+) were detectable in blood-derived cell-free DNA of patients with HCC (n = 22) but none of the control patients with liver cirrhosis (n = 9). Arm-level SCNAs on 1q+ or 8q+ are associated with high-risk liver pathology. These can be detected using low-pass sequencing of cell-free DNA isolated from blood, which may be a future early cancer screening tool for patients with liver cirrhosis. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
引用
- Fateen W, Johnson PJ, Wood HM, et al. Characterisation of dysplastic liver nodules using low-pass DNA sequencing and detection of chromosome arm-level abnormalities in blood-derived cell-free DNA. J Pathol. 2021. PMID: 34028025. doi:10.1002/path.5734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。